SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility

被引：63
作者：
Grieve, Richard [1 ]
Grishchenko, Marina [1 ]
Cairns, John [1 ]
机构：
[1] London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England
来源：
EUROPEAN JOURNAL OF HEALTH ECONOMICS | 2009年 / 10卷 / 01期
关键词：
Cost-utility; EQ-5D; SF-6D; Health utilities; CHRONIC HEPATITIS-C; PLUS RIBAVIRIN; HEALTH; PEGINTERFERON; EUROQOL; THERAPY;
D O I：
10.1007/s10198-008-0097-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
The choice of instrument (e.g. EQ-5D vs. SF-6D) can lead to different health-related utility scores, but it is unclear why these differences arise and whether they change cost utility analysis (CUA) results. This paper addresses these issues using a case study where using SF-6D rather EQ-5D led to greater utility gain and a lower cost per QALY for treatment. The paper examines reasons for this difference. This paper finds that an important factor was the inclusion in the SF-6D descriptive system of separate items for "vitality" and "social functioning", not explicitly included in EQ-5D. Further studies are required that examine the impact of the choice of instrument on cost-utility.
引用
收藏
页码：15 / 23
页数：9
相关论文
共 25 条
  • [11] Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C
    Grieve, R.
    Roberts, J.
    Wright, M.
    Sweeting, M.
    DeAngelis, D.
    Rosenberg, W.
    Bassendine, M.
    Main, J.
    Thomas, H.
    [J]. GUT, 2006, 55 (09) : 1332 - 1338
  • [12] Comparison of EQ-5D and SF-6D utilities in mental health patients
    Lamers, L. A.
    Bouwmans, C. A. M.
    van Straten, A.
    Donker, M. C. H.
    Hakkaart, L.
    [J]. HEALTH ECONOMICS, 2006, 15 (11) : 1229 - 1236
  • [13] An empirical comparison of EQ-5D and SF-6D in liver transplant patients
    Longworth, L
    Bryan, S
    [J]. HEALTH ECONOMICS, 2003, 12 (12) : 1061 - 1067
  • [14] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    Manns, MP
    McHutchison, JG
    Gordon, SC
    Rustgi, VK
    Shiffman, M
    Reindollar, R
    Goodman, ZD
    Koury, K
    Ling, MH
    Albrecht, JK
    [J]. LANCET, 2001, 358 (9286) : 958 - 965
  • [15] A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis
    Marra, CA
    Woolcott, JC
    Kopec, JA
    Shojania, K
    Offer, R
    Brazier, JE
    Esdaile, JM
    Anis, AH
    [J]. SOCIAL SCIENCE & MEDICINE, 2005, 60 (07) : 1571 - 1582
  • [16] Michaels J A, 2006, Health Technol Assess, V10, P1
  • [17] PICKARD SA, 2005, BMC HLTH QUAL LIFE O, V3, P1
  • [18] Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS
    Stavem, K
    Froland, SS
    Hellum, KB
    [J]. QUALITY OF LIFE RESEARCH, 2005, 14 (04) : 971 - 980
  • [19] Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fractures
    Tidermark, J
    Bergström, G
    Svensson, O
    Törnkvist, H
    Ponzer, S
    [J]. QUALITY OF LIFE RESEARCH, 2003, 12 (08) : 1069 - 1079
  • [20] Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets
    Tsuchiya, A
    Brazier, J
    Roberts, J
    [J]. JOURNAL OF HEALTH ECONOMICS, 2006, 25 (02) : 334 - 346
123